|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 HKD | -1.47% |
|
+4.69% | -8.22% |
| Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
| Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Ascletis Pharma Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 46.51 million compared to CNY 38.22 million a year ago. Net loss was CNY 16.56 million compared to CNY 88 million a year ago.
Basic loss per share from continuing operations was CNY 0.0152 compared to CNY 0.081 a year ago. Diluted loss per share from continuing operations was CNY 0.0152 compared to CNY 0.081 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.22% | 173M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
ASCLETIS PHARMA INC. 
